Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}imino)cyclohexa-2,5-dien-1-yl]acetonitrile
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the quinazolinamine class. It has been studied as an experimental agent and is not approved for clinical use in any country. The molecule features a quinazoline core with a pyrazole substituent and an acetonitrile group. Its mechanism of action includes inhibition of proto-oncogene tyrosine-protein kinase Src (SRC), which plays roles in cell proliferation and survival signaling pathways relevant to cancer biology[3][4]. It may also interact with other kinases such as calcium/calmodulin-dependent protein kinase type II subunit delta (CAMKIIδ)[2]. No clinical indications or marketed products are associated with this compound.
- Other names
- 2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile[4-{4-(5-cyclopropyl‑1H‑pyrazol‑3‑yl)amino}quinazolin‑2‑yl}imino)cyclohexa‑2,5-dien‑1‑yl]acetonitrile[4-{4-(5-CYCLOPROPYL–1H–PYRAZOL–3-YL)AMINO]QUINAZOLIN–2-YL}IMINO)CYCLOHEXA–2,5-DIEN–1-YL]ACETONITRILE
02
Targets
SRC (Proto-oncogene tyrosine-protein kinase Src)CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)
Beyond the preview
Go deeper on 2-[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}imino)cyclohexa-2,5-dien-1-yl]acetonitrile.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2-[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}imino)cyclohexa-2,5-dien-1-yl]acetonitrile.